Parvovirus 4 (PARV4) is a single‑stranded DNA virus classified in the family Parvoviridae (genus Tetraparvovirus). It was first identified in 2005 in the plasma of a febrile injection drug user and is characterized by a non‑enveloped icosahedral capsid about 25 nm in diameter. Three genotypes (PARV4–1, PARV4–2 and PARV4–3) circulate in human populations, but infection is uncommon outside specific high‑risk groups.
Explanation
Parvovirus 4 replicates as a small DNA virus and depends on helper viruses such as adenovirus for productive replication. Molecular analysis shows that its ~5 kilobase genome encodes non‑structural and capsid proteins typical of tetraparvoviruses. Since discovery, PARV4 DNA and antibodies have been detected in injection drug users, haemophiliacs, blood transfusion recipients and people co‑infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV). Serological surveys indicate that 95 % of HIV‑ and HCV‑co‑infected injection drug users have been exposed to PARV4, whereas seroprevalence among healthy individuals in Western countries is very low. Transmission appears to be primarily parenteral; the virus is rarely found in respiratory or gastrointestinal specimens. Viral DNA has been reported in plasma, bone marrow, liver, myocardium, skin and cerebrospinal fluid, showing its broad tissue distribution. Despite this, clinical symptoms directly attributable to PARV4 infection are few. The individual in whom the virus was discovered had pharyngitis, vomiting and joint pain; other reports link PARV4 DNA to encephalitis, but definitive proof of causation is lacking. Most infections appear to be asymptomatic or present with non‑specific flu‑like symptoms, and viral loads decline rapidly. There is no specific treatment or vaccine.
Clinical associations and research findings
High PARV4 seroprevalence in HIV/HCV‑co‑infected injection drug users suggests that shared risk factors such as needle use and blood exposure drive transmission. Studies have shown that PARV4‑positive status does not worsen HCV‑related liver disease but may be associated with early HIV‑related symptoms; however, this association is difficult to disentangle from confounding factors. T‑cell assays reveal robust effector memory responses to PARV4 antigens in coinfected individuals, indicating persistent immune stimulation. Reports of PARV4 DNA in cerebrospinal fluid and myocardium raise questions about potential neurological and cardiac manifestations. Because the virus is widely distributed globally and persists after acute infection, ongoing surveillance is important. Diagnostic assays include polymerase chain reaction (PCR) for viral DNA and enzyme‑linked immunosorbent assays to detect antibodies. In summary, Parvovirus 4 is a recently recognized human parvovirus transmitted mainly through blood exposure. It is highly prevalent in certain high‑risk populations but rarely detected in healthy people. Its pathogenic role remains uncertain, and more studies are needed to clarify its epidemiology and possible disease associations. Related Terms: Parvovirus B19, Human Bocavirus 2, Human Bocavirus 3, Human Bocavirus 4, Tetraparvovirus